Demographics and background parameters:
Study ID, Country of Origin, Sex, Race/ethnicity, Date of Birth

Sporadic or Familial presentation, Gestation duration, Birth Weight, Birth Length, Birth Head Circumference; Maternal height, Paternal Height, Sibling growth history

Growth disorder characteristics: Age at start of pathological growth (months), Age at diagnosis (months), Height SDS score at diagnosis, Height at diagnosis (cm), Bone Age/Chronological age (mo/yr), Appetite disturbance (y/n), weight SDS Score at diagnosis, Weight at diagnosis (kg), Head circumference SDS score at diagnosis, Head circumference at diagnosis (cm). Population-specific databases were used for calculation of height, weight and head circumference SDS.

Symptoms and hormone disturbances: Symptoms/signs at presentation; Galactorrhea (y/n), Pubertal stage at diagnosis, other hormonal axis disturbances; Fold upper limit of normal (ULN) for GH, Fold ULN for IGF-1, GH Suppressed on OGTT (y/n); TRH Test (y/n; effect), Fold ULN for Prolactin, GHRH test (y/n; effect), GHRH concentration

Pituitary imaging characteristics (modality); Tumor dimensions (mm), Maximum tumor diameter (mm), Macroadenoma (y/n), Invasion (y/n), Extension (y/n)

Treatment: Number of surgeries, Surgical outcome; Radiotherapy (y/n; type; dosage); Dopamine agonist (DA) (y/n; type, dose, duration), Decrease in prolactin with DA, Prolactin controlled by DA (y/n); Somatostatin analogs (SSA) (y/n; type/dose), Reduction in GH on SSA, Reduction in IGF-1 on SSA, Tumor shrinkage on SSA (y/n; %), Outcome (hormonal control) with SSA; Pegvisomant (y/n;dose, duration), Reduction in IGF-1 on pegvisomant, Outcome with pegvisomant; Cumulative treatments received (calculated as the sum of individual surgical interventions, radiotherapy, SSA (any use/period), DA (any use/period), pegvisomant (any use/period).

Outcomes: Age at control of pathological growth; Final height achieved (y/n; cm) Last follow up height (cm); Hypopituitarism (axes, replacement; diabetes insipidus (DI))

Pathology: Immunohistochemistry positivity, Cell types, Adenoma/Hyperplasia present (y/n)